The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized multicenter phase II trial of timed-sequential therapy with flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus “7+3” for adults with newly diagnosed acute myeloid leukemia (AML).
Joshua F. Zeidner
No relevant relationships to disclose
Matthew C. Foster
No relevant relationships to disclose
Amanda Blackford
No relevant relationships to disclose
Mark Robert Litzow
No relevant relationships to disclose
Lawrence Morris
No relevant relationships to disclose
Stephen Anthony Strickland
No relevant relationships to disclose
Jeffrey E. Lancet
No relevant relationships to disclose
Prithviraj Bose
No relevant relationships to disclose
M. Yair Levy
No relevant relationships to disclose
Raoul Tibes
No relevant relationships to disclose
Ivana Gojo
No relevant relationships to disclose
Christopher D Gocke
No relevant relationships to disclose
Gary L. Rosner
No relevant relationships to disclose
Jacqueline Greer
No relevant relationships to disclose
Joan M Cain
No relevant relationships to disclose
Richard F. Little
No relevant relationships to disclose
John Joseph Wright
No relevant relationships to disclose
L. Austin Doyle
No relevant relationships to disclose
B Douglas Smith
No relevant relationships to disclose
Judith E. Karp
No relevant relationships to disclose